6 research outputs found
PSO driven RBFNN for design of equilateral triangular microstrip patch antenna
233-237Recent advances in computer aided design packages for electromagnetic applications have helped antenna engineers to design, simulate and synthesize antennas efficiently. The PSO driven RBFNN has been developed to calculate the resonant frequency of equilateral triangular microstrip patch antenna (ETMPA). The present paper highlights the simplicity, computational efficiency and accuracy of the proposed method. The achieved results have been compared with published experimental and theoretical findings to validate the presented approach, which seems to be in very good agreements
Perceptions and experiences regarding the impact of race on the quality of healthcare in Southeast Brazil::a qualitative study
Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study
<div><p>Background</p><p>India is home to 60% of the total global visceral leishmaniasis (VL) population. Use of long-term oral (e.g. miltefosine) and parenteral drugs, considered the mainstay for treatment of VL, is now faced with increased resistance, decreased efficacy, low compliance and safety issues. The authors evaluated the efficacy and safety of an alternate treatment option, i.e. single infusion of preformed amphotericin B (AmB) lipid emulsion (ABLE) in comparison with that of liposomal formulation (LAmB).</p><p>Methods</p><p>In this multicentric, open-label study, 500 patients with VL were randomly assigned in a 3∶1 ratio to receive 15 mg/kg single infusion of either ABLE (N = 376) or LAmB (N = 124). Initial cure (Day 30/45), clinical improvement (Day 30) and long term definitive cure (Day 180) were assessed.</p><p>Findings</p><p>A total of 326 (86.7%) patients in the ABLE group and 122 (98.4%) patients in the LAmB group completed the study. Initial cure was achieved by 95.9% of patients in the ABLE group compared to 100% in the LAmB group (p = 0.028; 95% CI: −0.0663, −0.0150). Clinical improvement was comparable between treatments (ABLE: 98.9% vs. LAmB: 98.4%). Definitive cure was achieved in 85.9% with ABLE compared to 98.4% with LAmB. Infusion-related pyrexia (37.2% vs. 32.3%) and chills (18.4% vs. 18.5%) were comparable between ABLE and LAmB, respectively. Treatment-related serious adverse events were fewer in ABLE (0.3%) compared to LAmB (1.6%). Two deaths occurred in the ABLE group, of which one was probably related to the study drug. Nephrotoxicity and hepatotoxicity was not observed in either group.</p><p>Conclusions</p><p>ABLE 15 mg/kg single infusion had favorable efficacy and was well tolerated. Considering the demographic profile of the population in this region, a single dose treatment offers advantages in terms of compliance, cost and applicability.</p><p>Trial Registration</p><p><a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a><a href="http://www.clinicaltrials.gov/ct2/show/NCT00876824?term=NCT00876824" target="_blank">NCT00876824</a></p></div